Global challenges in the development and delivery of paediatric antiretrovirals

Drug Discovery Today

Volumn 13, Issue 11-12, 2008, Pages 530-535

  Bowen, Asha ^a,b   Palasanthiran, Pamela ^a,b   Sohn, Annette H ^c  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; AVOCOMB N KID; COVIRO LS KID; COVIRO LS KID DS; DIDANOSINE; EFAVIRENZ; EMDUO JUNIOR; EMDUO SUSPENSION; EMTRI JUNIOR; EMTRI SUSPENSION; GENERIC DRUG; GPOVIR S7; GPOVIR Z30; LAMIVIR S BABY; LAMIVIR S JUNIOR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIOIMMUNE BABY; TRIOIMMUNE JUNIOR; TRIVIRO LNS KID; TRIVIRO LNS KID DS; ZIDOVUDINE;

CHILD; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PEDIATRICS; REVIEW;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG COSTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; DRUGS, GENERIC; EVIDENCE-BASED MEDICINE; HEALTH SERVICES NEEDS AND DEMAND; HIV INFECTIONS; HUMANS; INFANT;

EID: 44649110178     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.03.018     Document Type: Review

References (55)

1. Blanche S., et al. Zidovudine therapy in children with acquired immunodeficiency syndrome. Am. J. Med. 85 (1988) 203-207
2. Pizzo P.A., et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. NEJM 319 (1988) 889-896
3. Havens P.L., and Gibb D.M. Increasing antiretroviral drug access for children with HIV infection. Pediatrics 119 (2007) 838-845
4. WHO, UNAIDS, UNICEF (2007) Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report. http://www.who.int/hiv/mediacentre/universal_access_progress_report_en.pdf (last accessed 25 November 2007)
5. UNAIDS (2007) AIDS epidemic update: December 2007. http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/default.asp (last accessed 17th April 2008)
6. Newell M.L., et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 364 (2004) 1236-1243
7. Dionisio D., et al. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?. Curr. HIV Res. 5 2 (2007) 155-187
8. Patel K., et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin. Infect Dis. 46 (2008) 507-515
9. Judd A., et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin. Infect Dis. 45 (2007) 918-924
10. Bolton-Moore C., et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 298 (2007) 1888-1899
11. Puthanakit T., et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 44 (2007) 599-604
12. Sirisanthana V. Demographic and clinical characteristic of symptomatic vertical HIV-infected children at Chiang Mai University Hospital. J. Infect Dis. Antimicrob. Agents 13 (1996) 89-93
13. Arrive, E et al. (2007) Response to anti-retroviral therapy (ART) in children in sub-Saharan Africa: a pooled analysis of clinical databases, the KIDS-ART-LINC Collaboration. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, United States of America, February 2007. Poster 727
14. Violari, A. et al. (2007) Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, July 2007. Abstract WESS103
15. Shirkey H. Therapeutic orphans. Pediatrics 104 3 Pt 2 (1999) 583-584
16. International, Treatment Preparedness Coalition (ITPC) (2007) Missing the target #5: Improving AIDS drug access and advancing health care for all, December 2007. http://www.aidstreatmentaccess.org (last accessed 3 December 2007)
17. Renaud-Thery F., et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS 21 Suppl. 4 (2007) S89-S95
18. Olson, D. et al. (2006) Antiretroviral therapy (ART) outcomes in children <13 years of age in resource-poor countries (RPCs): a Medecins sans Frontieres (MSF) cohort. AIDS 2006-XVI International AIDS Conference. Toronto, Canada, August 2006. Abstract MOAB0204
19. Olson, D. et al. (2006) Outcomes of children, stratified by immune status, receiving antiretroviral therapy (ART) in Medicins sans Frontiers (MSF)-supported projects in resource-poor countries (RPCs). AIDS 2006 - XVI International AIDS Conference. Toronto, Canada, August 2006. Abstract MOAB00203
20. WHO (2007) Antiretroviral therapy for HIV infection in infants and children: towards universal access, recommendations for a public health approach. http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf (last accessed 18 November 2007)
21. Janssens B., et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics 120 (2007) e1134-e1140
22. Puthanakit T., et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr. Infect. Dis. J. 26 (2007) 953-956
23. Song R., et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics 120 (2007) e856-e861
24. Eley B., et al. Antiretroviral treatment for children. S. Afr. Med. J. 96 9 Pt 2 (2006) 988-993
25. Puthanakit T., et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin. Infect. Dis. 41 (2005) 100-107
26. Chokephaibulkit K., et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS 19 (2005) 1495-1499
27. Veldkamp A.I., et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 15 (2001) 1089-1095
28. L'homme R.F., et al. Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. J. Antimicrob. Chemother. 59 (2007) 92-96
29. Questions and Answers on Pediatric HIV/AIDS Treatment (2007) http://www.cptech.org/ip/health/aids/2g/clinton-qa05082007.pdf (last accessed 25 November 2007)
30. Medicins sans Frontiers (2007) Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries, 10th edition. July 2007. http://www.accessmed-msf.org/resources/key-publications/key-publication-detail/article/untangling-the-web-10th-version-english (last accessed 25 November 2007)
31. WHO (2007) A summary report from the global price reporting mechanism on antiretroviral drugs, October 2007. http://www.who.int/hiv/amds/GPRMsummaryReportOct07.pdf (last accessed 18 December 2007)
32. WTO (1994) Annex 1C: Agreement on trade-related aspects of intellectual property rights. http://www.wto.org/english/docs_e/legal_e/27-trips.pdf (last accessed 21 December 2007)
33. Greco D.B., and Simao M. Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectives. AIDS 21 Suppl. 4 (2007) S37-S45
34. Ford N., et al. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS 21 Suppl. 4 (2007) S21-S29
35. WHO (2008) Access to HIV/AIDS Drugs and Diagnostics of acceptable quality. 63rd Edition 1st February 2008. http://www.who.int/prequal/lists/hiv_suppliers.pdf (last accessed 18 March 2008)
36. Office of International Programs, FDA (2007) PEPFAR: Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan. http://www.fda.gov/oia/pepfar.htm (last accessed 18 March 2008)
37. Krogstad P.A. Resistance to antiretroviral drugs: a threat to the prevention and treatment of pediatric HIV infection. J. Infect. Dis. 195 (2007) 1393-1395
38. Brogly S., et al. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA 293 (2005) 2213-2220
39. L'homme R.F., et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed dose combination tablets. AIDS 22 (2008) 557-565
40. Cressey, T. et al. (2007) IMPAACT P1056 Pharmacokinetics and safety of a novel pediatric fixed-dose combination versus the liquid formulations in HIV-infected Thai children: Pilot stage analysis. World Society of Pediatric Infectious Diseases. Bangkok, Thailand, November 2007 (no abstract number)
41. Pensi T. Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report. Indian Pediatr. J. 44 (2007) 519-521
42. Delaugerre C., et al. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children. J. Med. Virol. 79 (2007) 1261-1269
43. Arrive E., et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol. 36 (2007) 1009-1021
44. Lockman S., et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. NEJM 356 (2007) 135-147
45. Ramachandran G., et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J. Acquir. Immune Defic. Syndr. 42 (2006) 36-41
46. Ribera E., et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J. Acquir. Immune Defic. Syndr. 28 (2001) 450-453
47. Aurpibul, L. et al. (2007) Substitution of stavudine with zidovudine in HIV-infected children receiving HAART does NOT result in clinically significant hematologic changes. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 2007. Abstract TUPEB133
48. WHO. WHO expert working group meeting to determine preferred ARV medicines for treating and preventing HIV infection in younger children. Geneva. October 23-25, 2006. http://www.who.int/hiv/events/paediatricmeetingreport.pdf (last accessed 25 November 2007)
49. WHO Paediatric Antiretroviral Working Group (2008) Preferred antiretroviral medicines for treating and preventing HIV infection in younger children. http://www.who.int/hiv/events/paediatricmeetingreport.pdf (last accessed 13 March 2008)
50. Anabwani, G.M. et al. (2006) Long term response to highly active antiretroviral therapy among treatment naïve children in Botswana. AIDS 2006 - XVI International AIDS Conference, Toronto, Canada, August 2006. Abstract MOPE0261
51. Aurpibul, L. et al. (2007). Long-term effectiveness of NNRTI-based HAART in antiretroviral-naive HIV-infected children participating in Thailand́s National Access Program: 192-week result. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 2007. Abstract TUPEB127
52. Gafni R.I., et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118 (2006) e711-e718
53. Wiznia A., et al. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr. Infect. Dis. J. 26 (2007) 799-805
54. Kakuda, T.N. et al. (2008) Pharmacokinetics of the next generation NNRTI etravirine (ETR; TMC125) in HIV infected children between 6 and 17 years inclusive. 15th Conference on Retroviruses and Opportunistic Infections, Boston, United States of America, February, 2008. Abstract 578
55. Salazar, J. et al. (2006). Efficacy and safety results of 48 weeks of treatment with APTIVUS oral solution co-administered with low dose ritonavir (APTIVUS/r) in children and teenagers (Phase I/IIa study). AIDS 2006 - XVI International AIDS Conference, Toronto, Canada, August 2006. Abstract WEAB0301